Pharmacological studies have shown that administration of exogenous FGF21 at supraphysiological concentrations markedly improves conditions such as obesity, insulin resistance, and nonalcoholic fatty liver disease. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.